Pancreatic Cancer Research

ResearcherKindai UniversityActive in the last 2 years

Hitoshi Okada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5597-7212; OpenAlex author ID A5069440644. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers

Papers 4

  1. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Last author DOI 10.1038/s41419-024-06531-x↗
  2. Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Last author DOI 10.1038/s41419-024-06628-3↗
  3. ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer Cells. Co-author DOI 10.1155/2024/7683793↗
  4. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance. Last author DOI 10.1158/1541-7786.mcr-22-0554↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suman Dash · 3 shared papers, 2023–2024 · strength 0.72
  2. Golam Iftakhar Khandakar · 1 shared paper, 2024 · strength 0.21
  3. Teruaki Takasaki · 1 shared paper, 2024 · strength 0.21
  4. Kazuto Nishio · 1 shared paper, 2024 · strength 0.21
  5. Reiko Sugiura · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.